| |
BMI <30.0
|
BMI 30 to 34.9
|
BMI ≥ 35.0
| |
|---|
| |
Number (%)
|
Number (%)
|
Number (%)
|
P-valuea
|
|---|
|
Age at diagnosis, years
| | | |
<0.001
|
|
20 to 44
|
1,473 (34.2%)
|
138 (14.6%)
|
56 (13.0%)
| |
|
45 to 54
|
1,599 (37.1%)
|
284 (30.1%)
|
153 (35.5%)
| |
|
55 to 64
|
932 (21.6%)
|
364 (38.5%)
|
147 (34.1%)
| |
|
65 to 76
|
303 (7.0%)
|
159 (16.8%)
|
75 (17.4%)
| |
|
Median (percentiles 25 to 75)
|
48 (42 to 56)
|
56 (49 to 62)
|
55 (49 to 62)
| |
|
Menopausal status
| | | |
<0.001
|
|
Postmenopausal
|
1,737 (40.3%)
|
631 (66.8%)
|
293 (68.0%)
| |
|
Premenopausal
|
2,570 (59.7%)
|
314 (33.2%)
|
138 (32.0%)
| |
|
Histology
| | | |
0.730
|
|
Ductal
|
3,645 (84.6%)
|
788 (83.4%)
|
376 (87.2%)
| |
|
Lobulillar
|
385 (8.9%)
|
93 (9.8%)
|
32 (7.4%)
| |
|
Mixed
|
46 (1.1%)
|
12 (1.3%)
|
4 (0.9%)
| |
|
Others
|
230 (5.3%)
|
52 (5.5%)
|
19 (4.4%)
| |
|
Unknown
|
1 (0.0%)
|
0 (0.0%)
|
0 (0.0%)
| |
|
Histological grade
| | | |
0.054
|
|
1
|
384 (8.9%)
|
81 (8.6%)
|
34 (7.9%)
| |
|
2
|
1,792 (41.6%)
|
416 (44.0%)
|
196 (45.5%)
| |
|
3
|
1,823 (42.3%)
|
381 (40.3%)
|
187 (43.4%)
| |
|
Unknown
|
308 (7.1%)
|
67 (7.1%)
|
14 (3.2%)
| |
|
Pathologic primary tumor size
| | | |
<0.001
|
|
T1
|
2,192 (50.9%)
|
423 (44.8%)
|
179 (41.5%)
| |
|
T2
|
1,948 (45.2%)
|
485 (51.3%)
|
232 (53.8%)
| |
|
T3
|
167 (3.9%)
|
37 (3.9%)
|
20 (4.6%)
| |
|
Nodes
| | | |
0.021
|
|
Negative
|
2,278 (52.9%)
|
487 (51.5%)
|
198 (45.9%)
| |
|
Positive
|
2,029 (47.1%)
|
458 (48.5%)
|
233 (54.1%)
| |
|
Estrogen receptor
| | | |
0.647
|
|
Negative
|
1,398 (32.5%)
|
321 (34.0%)
|
137 (31.8%)
| |
|
Positive
|
2,899 (67.3%)
|
623 (65.9%)
|
291 (67.5%)
| |
|
Unknown
|
10 (0.2%)
|
1 (0.1%)
|
3 (0.7%)
| |
|
Progesterone receptor
| | | |
0.199
|
|
Negative
|
1,654 (38.4%)
|
373 (39.5%)
|
149 (34.6%)
| |
|
Positive
|
2,576 (59.8%)
|
558 (59.0%)
|
276 (64.0%)
| |
|
Unknown
|
77 (1.8%)
|
14 (1.5%)
|
6 (1.4%)
| |
|
Human epidermal growth factor-2 status
| | | |
0.030
|
|
Negative
|
3,036 (70.5%)
|
690 (73.0%)
|
329 (76.3%)
| |
|
Positive
|
656 (15.2%)
|
123 (13.0%)
|
51 (11.8%)
| |
|
Unknown
|
615 (14.3%)
|
132 (14.0%)
|
51 (11.8%)
| |
|
Type of surgery
| | | |
0.071
|
|
Mastectomy
|
2,021 (46.9%)
|
405 (42.9%)
|
195 (45.2%)
| |
|
Conservative
|
2,286 (53.1%)
|
540 (57.1%)
|
236 (54.8%)
| |
|
Hormonotherapy
| | | |
0.334
|
|
None
|
1,068 (24.8%)
|
256 (27.1%)
|
115 (26.7%)
| |
|
Yes
|
3,081 (71.5%)
|
664 (70.3%)
|
300 (69.6%)
| |
|
Unknown
|
158 (3.7%)
|
25 (2.6%)
|
16 (3.7%)
| |
|
Adverse events (grades 3,4)
| | | |
0.498
|
|
No
|
2,565 (59.6%)
|
578 (61.2%)
|
250 (58.0%)
| |
|
Yes
|
1,742 (40.4%)
|
367 (38.8%)
|
181 (42.0%)
| |
|
Initial under-treatment (in the first dose)
b
| | | |
<0.001
|
|
No
|
4,205 (97.6%)
|
922 (97.6%)
|
405 (94.0%)
| |
|
Yes
|
102 (2.4%)
|
23 (2.4%)
|
26 (6.0%)
| |
|
Per type of treatmentc
| | | | |
|
Epirubicin <85%
|
5 (0.5%)
|
5 (2.3%)
|
4 (4.0%)
|
0.002
|
|
Cyclophosphamide <85%
|
12 (0.3%)
|
4 (0.4%)
|
8 (1.9%)
|
<0.001
|
|
Fluorouracil <85%
|
8 (0.2%)
|
4 (0.5%)
|
7 (2.2%)
|
<0.001
|
|
Doxorubicin <85%
|
4 (0.1%)
|
3 (0.4%)
|
7 (2.1%)
|
<0.001
|
|
Docetaxel <85%
|
24 (2.5%)
|
5 (2.4%)
|
6 (5.4%)
|
0.199
|
|
Paclitaxel <85%
|
62 (5.2%)
|
11 (4.2%)
|
7 (6.7%)
|
0.604
|
|
Overall undertreatment
b
| | | |
<0.001
|
|
No
|
3,903 (90.6%)
|
820 (86.8%)
|
360 (83.5%)
| |
|
Yes
|
404 (9.4%)
|
125 (13.2%)
|
71 (16.5%)
| |
|
Per type of treatment c
| | | | |
|
Epirubicin <85%
|
50 (5.5%)
|
15 (6.8%)
|
13 (13.1%)
|
0.011
|
|
Cyclophosphamide <85%
|
213 (4.9%)
|
49 (5.2%)
|
34 (7.9%)
|
0.032
|
|
Fluorouracil <85%
|
132 (3.9%)
|
25 (3.4%)
|
24 (7.5%)
|
0.005
|
|
Doxorubicin <85%
|
160 (4.7%)
|
40 (5.5%)
|
26 (7.8%)
|
0.040
|
|
Docetaxel <85%
|
117 (15.8%)
|
39 (18.9%)
|
10 (9.9%)
|
0.068
|
|
Paclitaxel <85%
|
159 (13.3%)
|
59 (22.6%)
|
26 (25.0%)
|
<0.001
|
- aP-values computed excluding women without information in the corresponding variable; bdefined as total dose received lower than 85% of the theoretical dose prescribed; cpercentages including only women receiving the corresponding type of treatment. BMI, body mass index.
